Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.69 |
| ▸ | PLK2 | Q9NYY3 | 15/20 | 0.69 |
| ▸ | PLK3 | Q9H4B4 | 15/20 | 0.69 |
| ▸ | BRD4 | O60885 | 4/20 | 0.60 |
| ▸ | TAF1 | P21675 | 1/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | PRKCG | P05129 | 1/20 | 0.57 |
| ▸ | CLK2 | P49760 | 1/20 | 0.57 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.57 |
| ▸ | NEK4 | P51957 | 1/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.57 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.57 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.57 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.57 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.57 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032197 | 1.00 | PLK1 (0.69) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL761490 | 0.86 | PLK1 (0.61) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL27376920 | 0.86 | PLK1 (0.64) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL25785687 | 0.86 | PLK1 (0.80) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL13551775 | 0.85 | PLK1 (0.82) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL27369473 | 0.85 | PLK1 (0.82) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL17884568 | 0.85 | PLK1 (0.62) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL1828713 | 0.84 | PLK1 (0.60) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL1395135 | 0.84 | PLK1 (0.60) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL1395138 | 0.84 | PLK1 (0.60) | PLK1PLK2PLK3BRD4TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503586-B | Dihydropteridinone BRD4 protein inhibitor, preparation method and application thereof | 郑州大学 | 2021-05-07 | — | — | CN | disclosed |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | Elan Corporation, Inc. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445503-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2516441-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | PLK1 1/4885PLK2 23/4885PLK3 92/4885 |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | PLK1 1/4885PLK2 22/4885PLK3 101/4885 |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | PLK1 2/4885PLK2 18/4885PLK3 76/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | PLK1 1/4885PLK2 22/4885PLK3 101/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | PLK1 2/4885PLK2 18/4885PLK3 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.